 In previous studies, EBV CTLs were generated from the blood of the patient, which was often difficult if the patient had recently received chemotherapy. Also, it took up to 1-2 months to make the cells, which is not practical when a patient needs treatment more urgently. To address these issues, the T cells in the current study were made in the laboratory in a simpler, faster, and safer way. The T cells we have made will still see LMP proteins but also two other EBV proteins called EBNA-1 and BARF. These cells are called MABEL CTLs. In order to ensure these cells are available for use in patients in urgent clinical need, we have generated MABEL CTLs from the blood of healthy donors and created a bank of these cells, which are frozen until ready for use. We have previously successfully used frozen T cells from healthy donors to treat EBV lymphoma and virus infections and we now have improved our production method to make it faster. 